![Three University of Cincinnati researchers wearing lab coats stand at a laboratory counter reviewing data on a computer](https://www.uc.edu/news/articles/2023/02/n21145526/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1675788100619.jpg)
Making pancreatic cancer treatments more effective
NCI to fund research on targeted treatments, processes that drive drug resistance
Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.
The American Cancer Society estimates approximately 64,000 Americans will be diagnosed with pancreatic cancer this year, and approximately 50,500 people in the U.S. will die of pancreatic cancer in 2023. While currently the third-leading cause of cancer death in the United States, pancreatic cancer is expected to become the second-leading cause of cancer death by 2030, highlighting the need for new and innovative treatments.
More than 90% of pancreatic cancers are driven by mutations in a certain gene called KRAS. The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
KRAS basics
In healthy human cells, the KRAS gene acts as a “light switch” telling cells when to divide.
“In the on position, cells divide. In the off position, cells stop dividing. It is tightly controlled, regulated, and balanced,” said Waters, University of Cincinnati Cancer Center researcher and assistant professor in the UC College of Medicine’s Department of Surgery, Division of Surgical Oncology and Department of Cancer Biology. “When you have a mutation in KRAS, the light switch can’t be turned off, and cells divide uncontrollably. If left unchecked, this can lead to pancreatic cancer.”
The KRAS gene mutations were discovered more than 40 years ago, but it was considered not able to be treated by drugs, or “undruggable,” for decades. Drawn to difficult problems, Waters said the challenge of KRAS appealed to him as an area where he could make a difference.
“Initially when I heard almost all pancreatic cancers had a mutation in the KRAS gene, and it was undruggable, this seemed like somewhere I could potentially contribute,” he said. “As I learned more and more about KRAS, it became a passion of mine, and now I am hooked.”
Andrew Waters uses a microscope to analyze cell samples in his laboratory. Photo/Andrew Higley/UC Marketing + Brand.
The Food and Drug Administration recently approved the first two drugs that target one particular KRAS mutation, but the drugs have a limited use in pancreatic cancer. While the KRAS mutation that the drugs target is common in lung cancers, it is rare in pancreatic cancers.
“About 98% to 99% of KRAS-mutant pancreatic cancer patients have other KRAS mutations and will not benefit from this class of drugs,” said Waters. “We need KRAS drugs that target the KRAS mutations that occur in pancreatic cancer.”
The recently approved KRAS drugs are also limited because like with all targeted therapies, the cancer cells eventually develop resistance to the targeted treatment, Waters said.
“Because we know relapse will occur, we need to identify the resistance mechanisms in pancreatic cancer that drive the relapse in order to develop KRAS inhibitor combination approaches,” he said.
Grace Goodhart, research associate, pipettes samples in Waters' lab. Photo/Andrew Higley/UC Marketing + Brand.
Grant-funded research
The NCI intends to fund Waters’ lab through an approximately $587,000, three-year career development grant. With the funds, Waters will test clinically relevant drugs that target two particular KRAS mutations more commonly found in pancreatic cancer. The drugs being tested are novel, unpublished formulations that will be studied both through cell lines and animal models.
Waters will also study the specific mechanisms within KRAS-mutated pancreatic cancer cells that lead to resistance to targeted treatments. Some of these processes may be similar to resistance processes found in KRAS-mutated lung cancer cells, but Waters said there is growing evidence that each mutation is different.
“Until somewhat recently, almost everyone thought all KRAS mutations are equal,” he said. “I hypothesize different mutations will have some distinct resistance mechanisms. In the era of personalized medicine, this is extremely important, because understanding these mutation-specific resistance mechanisms can potentially guide treatment options in a personalized way.”
With more knowledge on what drugs effectively treat KRAS-mutated pancreatic cancer and what causes drug resistance, the goal is to increase the efficacy and longevity of KRAS-targeted treatments for pancreatic cancer patients.
Andrew Waters and Grace Goodhart collaborate in the lab. Photo/Andrew Higley/UC Marketing + Brand.
Personal motivation
As his work continues, Waters said he continues to be motivated by pancreatic cancer patients, volunteer work with organizations like the Pancreatic Cancer Action Network and the personal effect cancer has had on his life.
“I have lost many family members and close friends to cancer, and some of those people that I lost have been my biggest supporters,” he said.
Waters said his path to joining UC’s faculty has been unconventional, including work at biotech companies and conducting his doctoral research at the Frederick National Laboratory for Cancer Research.
“National laboratories are funded by the federal government so there isn’t a big push to apply for grants and secure additional external funding,” he said. “To receive the best possible score on my first independent grant application from the NCI, arguably the most competitive division of the National Institutes of Health, feels very validating.”
Read about additional pancreatic cancer research at UC led by Krushna Patra.
Featured photo at top: Researchers Krushna Patra, Andrew Waters and Patrick Krause review data. Photo/Andrew Higley/UC Marketing + Brand.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Bono, Chris Tucker Visit UC To Discuss Africa
December 5, 2002
U2's Bono and comedian-actor Chris Tucker led a delegation from the DATA organization who came to UC to talk about potentially catastrophic problems in Africa.
New Year's Help for Those Looking to Kick the Habit
December 20, 2002
Quitting smoking consistently ranks among the top three resolutions made by New Year's resolvers each year.
E-BRIEF: Let's Toast to a Healthier 2003
January 8, 2003
The New Year often means a new health kick: Vows to tone up and trim down, and maybe going to the doctor and getting ourselves as regularly "maintenanced" as we do our cars. So, this week's University of Cincinnati e-briefing examines the health concerns of the young and old, and what you should be doing to preserve your good health.
Today's ML King Events: One On, One Off
January 8, 2003
A memorial march, presentations, poetry and dance will pay tribute to the slain civil rights leader.
UC Named Lead Organization for OSHA Training Consortium
January 13, 2003
UC Continuing Medical Education (CME) has been selected as the lead organization for the Occupational Safety and Health Administration (OSHA) Great Lakes Training Consortium by the U.S. Department of Labor.
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 13, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 14, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 20, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 21, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
Leader of Fetal Surgery to Deliver Lectures at UC
January 31, 2003
An internationally recognized authority on fetal surgery will lecture at the UC Medical Center, representing the first of a series of lectures on fetal surgery presented by the department of Obstetrics and Gynecology (Ob/Gyn).